Complementing this metabolite-centric view, intratumoral microbiota can directly alter drug pharmacology: Geller et al. demonstrated that tumor-resident bacteria possessing cytidine deaminase activity can inactivate gemcitabine, thereby diminishing cytotoxicity [112]. This evidence concerns the gene CDA and neoplasm.